Citation
Khunti K, Seidu S, Davies MJ. Should sodium-glucose co-transporter-2 inhibitors be considered as first-line oral therapy for people with type 2 diabetes? Diabetes Obes Metab. 2019;21(2):207-9.
Abstract
Type 2 diabetes mellitus is a chronic condition associated with long‐term microvascular and macrovascular complications. Evidence‐based guidelines recommend the individualization of therapies to manage hyperglycaemia in order to reduce the risk of complications.